Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06107764 · ClinicalTrials.gov registry record · NA

Cerebellar Modulation of Cognition in Psychosis

A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Mclean Hospital.

Recruiting
Registry status
NA
Development phase
95
Enrollment target
2
Study locations

NCT06107764: Recruiting NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Mclean Hospital.

NCT06107764 is a NA study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 95 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06107764, a NA study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by Mclean Hospital.

RECRUITING
Registry status
NA
Development phase
95 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Participants will be asked to perform cognitive tasks (problem-solving) and undergo brain scans before and after transcranial magnetic stimulation (TMS). TMS is a way to non-invasively change brain activity. Forms of TMS are FDA-approved to treat depression and obsessive compulsive disorder. In this study, we will use a different form of TMS to temporarily change brain activity to observe how that changes speed in problem-solving.

Primary Outcome

The BACS Symbol coding test is a test of information processing speed

Interventions

  • DEVICE sham rTMS
  • DEVICE intermittant theta burst stimulation (iTBS)
  • DEVICE continuous theta burst stimulation (cTBS)

Study Locations (2)

Massachusetts

  • McLean Hospital - Belmont
  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2024-07-31
Est. Completion 2029-12
Phase NA
Mclean Hospital

140 total trials

What NCT06107764 shows while recruiting

NCT06107764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (57% lower).

The record links to 4 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which sham rTMS is the first listed.

NCT06107764 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06107764 about?

NCT06107764 is a clinical study titled "Cerebellar Modulation of Cognition in Psychosis". The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Pa...

What is the current status of trial NCT06107764?

This trial is currently recruiting. It is a NA study. The enrollment target is 95 participants. The study started on 2024-07-31. Estimated completion is 2029-12.

What conditions does trial NCT06107764 study?

This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Psychosis, Bipolar Disorder I.

What interventions are being tested in trial NCT06107764?

The interventions under investigation include: sham rTMS (DEVICE), intermittant theta burst stimulation (iTBS) (DEVICE), continuous theta burst stimulation (cTBS) (DEVICE).

Who is sponsoring clinical trial NCT06107764?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06107764 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06107764's enrollment target sits among peer trials

95 150th of 315 higher than 166 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03339128 · 95 participants · Phase 2

    Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

  • NCT03509961 · 95 participants · Phase 2

    The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • NCT03694756 · 95 participants · NA

    TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

  • NCT04206215 · 95 participants · NA

    Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06107764, the US trial registry maintained by the National Library of Medicine. NCT06107764 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.